Latest QLGN reports update at 2023-11-14: 2023-Q3 ∙ 2022-Q4 ∙ 2022-Q3

Qualigen Therapeutics QLGN

$ 0.28 1.14%

Qualigen Therapeutics Balance Sheet 2011-2024 | QLGN

Annual Balance Sheet Qualigen Therapeutics

	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-5.49 M	-15.9 M	2.07 M	-1.7 M	-7.81 M	-22.6 M	-7.05 M	-15.8 M	-	-	-	-
Long Term Debt	1.3 M	1.54 M	306 K	-	-	-	-	-	-	-	-	-
Long Term Debt Current	241 K	134 K	255 K	100 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	308 K	-	-	-	-	-	-	-	-	-
Total Current Liabilities	8.61 M	4.64 M	10.4 M	1.7 M	5.93 M	2.71 M	3.13 M	1.35 M	-	-	-	-
Total Liabilities	10.3 M	6.27 M	5.65 M	1.7 M	5.93 M	2.71 M	3.13 M	1.35 M	-	-	-	-
Deferred Revenue	-	-	377 K	-	-	-	-	-	-	-	-	-
Retained Earnings	-103 M	-84.7 M	-47.3 M	-80.3 M	-70.2 M	-53.3 M	-45.5 M	-27.1 M	-	-	-	-
Total Assets	19.1 M	22.8 M	3.72 M	2.8 M	15.3 M	22.8 M	7.24 M	16 M	-	-	-	-
Cash and Cash Equivalents	7.03 M	17.5 M	24 M	1.7 M	7.81 M	22.6 M	7.05 M	15.8 M	2.75 M	-	-	-
Book Value	8.77 M	16.6 M	-1.93 M	1.1 M	9.39 M	20.1 M	4.1 M	14.7 M	-	-	-	-
Total Shareholders Equity	7.24 M	16.6 M	18.3 M	1.1 M	9.39 M	20.1 M	4.1 M	14.7 M	-14.5 M	-	-	-

All numbers in USD currency

Quarterly Balance Sheet Qualigen Therapeutics

	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	1.17 M	1.24 M	1.3 M	1.37 M	1.43 M	1.48 M	1.54 M	25 K	98.1 K	15.6 K	139 K	947 K	1.33 M	2.22 M	-	10.3 K	40.8 K	70.9 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	70 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	5.96 M	9.84 M	9.71 M	10.3 M	7.04 M	7.88 M	5.19 M	6.27 M	5.56 M	7.63 M	9.51 M	10.8 M	10.8 M	10.8 M	10.8 M	-	2.84 M	2.88 M	4.13 M	5.93 M	-	5.93 M	5.93 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	-	95.2 K	95.2 K	69.6 K	105 K	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Retained Earnings	-114 M	-111 M	-107 M	-103 M	-97 M	-93.2 M	-89.1 M	-84.7 M	-78.7 M	-75.8 M	-70.5 M	-66.8 M	-66.8 M	-66.8 M	-66.8 M	-80.3 M	-79.9 M	-77.7 M	-74.9 M	-70.2 M	-70.2 M	-70.2 M	-70.2 M	-53.3 M	-53.3 M	-53.3 M	-53.3 M	-45.5 M	-45.5 M	-45.5 M	-45.5 M	-27.1 M	-27.1 M	-27.1 M	-27.1 M	-17.9 M	-17.9 M	-17.9 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Assets	4.32 M	13.1 M	15.9 M	19.1 M	23 M	26.3 M	18.7 M	22.8 M	16.4 M	19.9 M	25.7 M	29.1 M	29.1 M	29.1 M	29.1 M	2.8 M	2.9 M	5.01 M	8.96 M	15.3 M	15.3 M	15.3 M	15.3 M	22.8 M	22.8 M	22.8 M	22.8 M	7.24 M	7.24 M	7.24 M	7.24 M	16 M	16 M	16 M	16 M	2.96 M	2.96 M	2.96 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	2.07 M	1.34 M	4.36 M	3.17 M	6.62 M	9.75 M	13.6 M	17.5 M	12.3 M	15.2 M	21.9 M	24 M	14.5 M	24 M	24 M	1.7 M	1.96 M	71.2 K	5.52 M	7.81 M	7.81 M	7.81 M	7.81 M	22.6 M	22.6 M	22.6 M	22.6 M	7.05 M	7.05 M	7.05 M	7.05 M	15.8 M	15.8 M	15.8 M	15.8 M	2.75 M	2.75 M	2.75 M	-	448 K	-	-	-	-	-	-	-	-	-	-	-
Book Value	-1.64 M	3.31 M	6.2 M	8.77 M	15.9 M	18.5 M	13.5 M	16.6 M	10.8 M	12.3 M	16.2 M	18.3 M	18.3 M	18.3 M	18.3 M	2.8 M	62.9 K	2.14 M	4.83 M	9.39 M	15.3 M	9.39 M	9.39 M	22.8 M	22.8 M	22.8 M	22.8 M	7.24 M	7.24 M	7.24 M	7.24 M	16 M	16 M	16 M	16 M	2.96 M	2.96 M	2.96 M	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Shareholders Equity	-1.64 M	2.03 M	6.2 M	7.24 M	15.9 M	18.5 M	13.5 M	16.6 M	10.7 M	12.3 M	16.2 M	18.3 M	18.3 M	18.3 M	18.3 M	-1.06 M	-1.1 M	-743 K	1.1 M	9.39 M	9.39 M	9.39 M	9.39 M	20.1 M	20.1 M	20.1 M	20.1 M	4.14 M	4.1 M	4.1 M	4.1 M	14.7 M	14.7 M	14.7 M	14.7 M	-14.5 M	-14.5 M	-14.5 M	-	-12.8 M	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency